GPR113 Antibody

What is GPR113 and what cellular processes does it regulate?

GPR113 (also known as ADGRF3) belongs to the adhesion G protein-coupled receptor family, which plays important roles in signal transduction across cellular membranes. These receptors typically undergo autoproteolytic cleavage that generates N-terminal and C-terminal fragments, with the dissociation of these fragments often correlating with receptor activation and downstream signaling events . Similar to its family member GPR133 (ADGRD1), GPR113 likely participates in G protein-coupled signaling pathways, potentially involving cAMP elevation, though the specific signaling cascades may differ between various adhesion GPCRs . Understanding these mechanisms is critical for research involving GPR113 antibodies as tools for receptor modulation or detection.

What types of GPR113 antibodies are currently available for research applications?

Current research-grade GPR113 antibodies include polyclonal antibodies derived from rabbit hosts. Specific examples include the rabbit polyclonal antibody to GPR113 that detects endogenous levels of GPR113 protein, with reactivity to human samples . Another available antibody is the rabbit polyclonal against GPR113/ADGRF3 with broader species reactivity across human, mouse, and rat samples . These antibodies have been developed using different immunogens - one derived from the N-terminal region of human GPR113 , and another using a peptide derived from human GPR113 corresponding to amino acid positions 21-70 . The selection of an appropriate antibody depends on the experimental model and specific research requirements.

What validation methods should be employed to confirm GPR113 antibody specificity?

Validation of GPR113 antibodies should follow a multi-parameter approach to ensure specificity and functionality:

• Western blot analysis using positive control samples (e.g., HeLa cells) to confirm the detection of endogenous GPR113 at the expected molecular weight of approximately 72-116 kDa

• ELISA under non-permeabilizing conditions to verify binding to the native protein

• Antibody titration experiments to establish concentration-dependent binding, which can be measured by optical density increases proportional to antibody concentration

• Negative controls including sodium azide (NaN₃) treatments at matching concentrations to rule out non-specific effects

• Competitive binding assays with epitope-specific blocking peptides to confirm binding specificity

Researchers should note that antibody validation should ideally be performed in their specific experimental system to account for potential variations in protein expression and processing.

How can cAMP assays be optimized to measure GPR113 antibody-mediated receptor activation?

Based on related research with the GPR133 receptor, homogeneous time-resolved fluorescence (HTRF)-based assays provide a sensitive method to quantify changes in intracellular cAMP levels following antibody treatment . To optimize these assays for GPR113 studies:

• Establish baseline cAMP levels in cells expressing GPR113 compared to empty vector controls

• Test a range of antibody concentrations (typically from nanomolar to micromolar) to establish dose-response relationships

• Include appropriate solvent controls (e.g., matching concentrations of NaN₃ if present in antibody formulations)

• Implement positive controls such as forskolin to verify assay functionality

• Consider time-course experiments to determine optimal incubation periods

For statistical analysis, two-way ANOVA with appropriate post-hoc tests (e.g., Tukey's) should be employed to assess significance between treatment groups . Researchers should establish concentration-response curves to determine EC₅₀ values for antibody-mediated receptor activation, which can facilitate comparisons between different antibody preparations or experimental conditions.

What strategies can enhance GPR113 antibody effectiveness in cellular signaling studies?

Research with related adhesion GPCRs suggests several approaches to enhance antibody-mediated effects on receptor signaling:

• Antibody clustering approach: Coupling antibodies to magnetic beads (e.g., Dynabeads) can increase their effective concentration at the cell surface and potentially enhance receptor activation. This approach has shown significant potentiation of signaling compared to soluble antibodies alone in studies with GPR133 .

• Epitope selection: Targeting specific domains outside the GAIN (GPCR Autoproteolysis-INducing) domain may produce different functional outcomes. Antibodies targeting the PTX domain or other N-terminal regions may have distinct effects on receptor activation .

• Multi-parameter assessment: When evaluating antibody effects, researchers should measure both:

  • Intracellular signaling (e.g., cAMP levels)

  • Receptor processing (e.g., presence of antibody-NTF complexes in culture medium)

Table 1: Comparison of Methods for Enhancing Antibody-Mediated GPR113/GPR133 Activation

How does receptor cleavage affect GPR113 antibody function, and how can this be experimentally assessed?

The autoproteolytic cleavage of adhesion GPCRs appears to be critical for antibody-mediated activation. Research with GPR133 demonstrates that cleavage-deficient mutants (e.g., H543R) do not respond to antibody stimulation despite normal antibody binding . To investigate the role of cleavage in GPR113 function:

• Generate cleavage-deficient GPR113 mutants through site-directed mutagenesis at the GPS (GPCR proteolysis site) domain

• Compare antibody responses between wild-type and cleavage-deficient variants using:

  • cAMP assays to measure downstream signaling

  • ELISA to confirm antibody binding under non-permeabilizing conditions

  • Western blot analysis to verify the presence or absence of cleaved fragments

• Analyze culture medium for the presence of:

  • Antibody-N-terminal fragment (NTF) complexes

  • Changes in NTF shedding following antibody treatment

This experimental approach can provide insights into whether the mechanism of antibody-mediated GPR113 activation resembles that of GPR133, where antibody binding appears to promote the dissociation of autoproteolytically generated fragments .

What are the optimal storage and handling conditions for maintaining GPR113 antibody activity?

To preserve the functionality of GPR113 antibodies:

• Store concentrated antibody stocks at -20°C for long-term storage (up to 1 year)

• For frequent use and short-term storage (up to one month), maintain at 4°C

• Avoid repeated freeze-thaw cycles which can lead to antibody degradation and loss of activity

• Store in the recommended formulation: PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• When diluting for assays, use appropriate buffers that maintain protein stability (e.g., PBS with 1% BSA)

These storage conditions apply to both the Anti-GPR113 Antibody (A40384) and Anti-GPR113 ADGRF3 Antibody (A30798), though researchers should always verify specific recommendations for each antibody preparation they use .

What experimental controls are essential when using GPR113 antibodies in functional studies?

Rigorous experimental controls are crucial for reliable interpretation of results when using GPR113 antibodies:

• Negative controls:

  • Empty vector-transfected cells to establish baseline signaling

  • Isotype-matched non-specific antibodies to control for non-specific binding effects

  • Solvent controls (e.g., matching NaN₃ concentrations) to account for buffer effects

  • Non-targeting antibodies (e.g., anti-FLAG for extracellular epitopes) to control for non-specific effects of antibody treatment

• Positive controls:

  • Known activators of cAMP pathways (e.g., forskolin) to verify assay functionality

  • Well-characterized antibodies against related receptors with established effects

• Validation controls:

  • Peptide competition assays to confirm binding specificity

  • Western blot analysis to verify the detection of GPR113 at the expected molecular weight (72-116 kDa)

  • Binding verification through ELISA or immunofluorescence under non-permeabilizing conditions

What are the recommended working dilutions for GPR113 antibodies in different applications?

Based on the available technical information, researchers should consider the following dilution ranges for GPR113 antibodies:

Table 2: Recommended Working Dilutions for GPR113 Antibodies

These ranges provide starting points for assay optimization. The actual working concentration should be determined empirically for each specific application, antibody lot, and experimental system .

How can researchers address inconsistent GPR113 antibody performance across different experimental systems?

Variability in antibody performance may stem from several factors:

• Receptor expression levels: Confirm GPR113 expression in your experimental system using RT-PCR or Western blot. Low endogenous expression may require overexpression systems for detectable responses.

• Post-translational modifications: Different cell types may process GPR113 differently. Analyze receptor cleavage and glycosylation patterns through Western blot using reducing and non-reducing conditions.

• Receptor conformational states: The conformation of GPR113 may differ between cell types or culture conditions. Consider using multiple antibodies targeting different epitopes to capture various receptor states.

• Methodological factors:

  • Verify antibody integrity through SDS-PAGE

  • Test different batches or sources of antibodies

  • Optimize fixation protocols for immunocytochemistry applications

  • Validate secondary antibody specificity

• Signal detection sensitivity: For weak signals, consider:

  • Signal amplification methods (e.g., TSA for immunohistochemistry)

  • More sensitive detection systems for Western blot

  • Longer exposure times balanced against background concerns

What approaches can resolve contradictory results between different GPR113 antibody-based assays?

When facing discrepancies between assay results:

• Assess epitope accessibility: Different assay formats (e.g., Western blot versus ELISA) expose different epitopes. Antibodies recognizing conformational epitopes may function in ELISA but not in denaturing Western blots.

• Compare antibody binding versus functional effects: An antibody may bind to GPR113 (detectable by ELISA) without affecting receptor function, or vice versa. Systematically compare binding data with functional outcomes.

• Evaluate assay kinetics: Time-course experiments can reveal differences in the kinetics of antibody binding versus downstream signaling events.

• Consider cellular context: Results may differ between recombinant systems and endogenous expression. Validate findings in multiple cell types relevant to your research question.

• Employ complementary approaches: Supplement antibody-based studies with genetic approaches (e.g., CRISPR-Cas9 receptor modification) to build a more robust understanding of receptor function.

How might advances in antibody engineering enhance GPR113 research tools?

Emerging antibody technologies offer several opportunities to develop enhanced GPR113 research tools:

• Single-domain antibodies (nanobodies): Their small size may provide access to epitopes inaccessible to conventional antibodies, potentially offering new ways to modulate GPR113 function.

• Bispecific antibodies: These could simultaneously target GPR113 and downstream signaling components, providing more precise control over signaling outcomes.

• Conformation-specific antibodies: Developing antibodies that specifically recognize active versus inactive states of GPR113 would enable more precise monitoring of receptor activation.

• Photoactivatable antibodies: These could allow temporal control over GPR113 modulation, facilitating the study of signaling kinetics and cellular responses.

• Antibody-drug conjugates: While primarily developed for therapeutic applications, this technology could be adapted to deliver specific modulators to GPR113-expressing cells in complex experimental systems.

What is the potential relationship between GPR113 and related adhesion G protein-coupled receptors in experimental systems?

Understanding the interrelationships between GPR113 and other adhesion GPCRs could inform experimental design and data interpretation:

• Sequence and structural homology: Comparative analysis between GPR113 (ADGRF3) and GPR133 (ADGRD1) might reveal conserved functional domains that could be targeted by similar experimental approaches.

• Shared signaling pathways: Both GPR113 and GPR133 may activate overlapping G protein-coupled pathways, suggesting potential crosstalk in systems where both receptors are expressed .

• Differential expression patterns: Mapping the expression of GPR113 versus other family members across tissues and disease states could identify optimal experimental systems for studying receptor-specific functions.

• Antibody cross-reactivity assessment: Careful validation is needed to ensure GPR113 antibodies do not cross-react with closely related family members, particularly in studies of endogenous receptor expression.

• Functional compensation: In knockout or knockdown studies, researchers should consider whether other adhesion GPCRs might compensate for GPR113 loss, potentially masking phenotypic effects.